Evidence Level
Preliminary
Vanadium research is primarily preclinical, with limited but intriguing human data. The seminal human studies by Cohen et al. (1995) and Halberstam et al. (1996) demonstrated improved insulin sensitivity and glucose control with vanadyl sulfate (100mg/day for 3 weeks) in small groups of type 2 diabetes patients (n=6-16). However, GI side effects were common, and no long-term safety data exists. The NIH UL for vanadium is only 1.8mg/day, yet therapeutic doses provide 8-31mg elemental vanadium — a significant concern. Research has largely shifted toward organic vanadium compounds (like BMOV) with better absorption and potentially lower toxicity, but these are not available as consumer supplements.